Literature DB >> 29326043

Upregulation of CDCA5 promotes gastric cancer malignant progression via influencing cyclin E1.

Zhengyuan Zhang1, Mingyang Shen2, Guangrong Zhou3.   

Abstract

The cell division cycle associated 5(CDCA5) was reported to be associated with progression of several human cancers, however, its clinical significance and biological role still remain unknown in gastric cancer(GC). By analyzing The Cancer Genome Atlas(TCGA), we found CDCA5 was significantly upregulated in GC tissues compared to adjacent normal tissues. Tissue microarray(TMA) indicated upregulation of CDCA5 was significantly correlated with more advanced clinicopathological features, and acts as an independent risk factor for worse overall survival(OS) in GC patients. Moreover, silence of CDCA5 suppresses proliferation of GC cells by inducing G1-phase arrest via downregulating Cyclin E1(CCNE1). Our results demonstrate upregulation of CDCA5 promotes GC malignant progression, which may offer a potential prognostic and therapeutic strategy.
Copyright © 2018 Elsevier Inc. All rights reserved.

Entities:  

Keywords:  Cell cycle; Cell division cycle associated 5(CDCA5); Gastric cancer(GC); Prognosis; Proliferation

Mesh:

Substances:

Year:  2018        PMID: 29326043     DOI: 10.1016/j.bbrc.2018.01.046

Source DB:  PubMed          Journal:  Biochem Biophys Res Commun        ISSN: 0006-291X            Impact factor:   3.575


  17 in total

1.  LINC01515 promotes nasopharyngeal carcinoma progression by serving as a sponge for miR-325 to up-regulate CDCA5.

Authors:  Dan Liu; Hao Gong; Zezhang Tao; Shiming Chen; Yonggang Kong; Bokui Xiao
Journal:  J Mol Histol       Date:  2021-03-26       Impact factor: 2.611

2.  Co-expression Network Analysis of Biomarkers for Adrenocortical Carcinoma.

Authors:  Lushun Yuan; Guofeng Qian; Liang Chen; Chin-Lee Wu; Han C Dan; Yu Xiao; Xinghuan Wang
Journal:  Front Genet       Date:  2018-08-15       Impact factor: 4.599

3.  CDCA5 promotes the progression of prostate cancer by affecting the ERK signalling pathway.

Authors:  Junpeng Ji; Tianyu Shen; Yang Li; Yixi Liu; Zhiqun Shang; Yuanjie Niu
Journal:  Oncol Rep       Date:  2021-01-04       Impact factor: 3.906

4.  GLI3 Promotes Invasion and Predicts Poor Prognosis in Colorectal Cancer.

Authors:  Mingyang Shen; Zhengyuan Zhang; Ping Wang
Journal:  Biomed Res Int       Date:  2021-01-09       Impact factor: 3.411

5.  Effective inhibition of MYC-amplified group 3 medulloblastoma by FACT-targeted curaxin drug CBL0137.

Authors:  Jiajia Wang; Yi Sui; Qifeng Li; Yang Zhao; Xiaoshu Dong; Jian Yang; Zhuangzhuang Liang; Yipeng Han; Yujie Tang; Jie Ma
Journal:  Cell Death Dis       Date:  2020-12-02       Impact factor: 8.469

6.  Cyclin-Dependent Kinase 1 (CDK1) is Co-Expressed with CDCA5: Their Functions in Gastric Cancer Cell Line MGC-803.

Authors:  Zhigang Huang; Shizhuo Zhang; Jinlin Du; Xing Zhang; Weijian Zhang; Zhaowei Huang; Ping Ouyang
Journal:  Med Sci Monit       Date:  2020-08-06

7.  Silencing of CDCA5 inhibits cancer progression and serves as a prognostic biomarker for hepatocellular carcinoma.

Authors:  Jianlin Wang; Congcong Xia; Meng Pu; Bin Dai; Xisheng Yang; Runze Shang; Zhen Yang; Ruohan Zhang; Kaishan Tao; Kefeng Dou
Journal:  Oncol Rep       Date:  2018-07-17       Impact factor: 3.906

8.  Identifying Tumorigenesis and Prognosis-Related Genes of Lung Adenocarcinoma: Based on Weighted Gene Coexpression Network Analysis.

Authors:  Ming Yi; Tianye Li; Shuang Qin; Shengnan Yu; Qian Chu; Anping Li; Kongming Wu
Journal:  Biomed Res Int       Date:  2020-02-28       Impact factor: 3.411

9.  Higher expression of cell division cycle-associated protein 5 predicts poorer survival outcomes in hepatocellular carcinoma.

Authors:  Shengzhong Hou; Xing Chen; Mao Li; Xing Huang; Haotian Liao; Bole Tian
Journal:  Aging (Albany NY)       Date:  2020-07-21       Impact factor: 5.682

10.  CDCA1/2/3/5/7/8 as novel prognostic biomarkers and CDCA4/6 as potential targets for gastric cancer.

Authors:  Zhaoxing Li; Zhao Liu; Chuang Li; Qingwei Liu; Bibo Tan; Yu Liu; Yifei Zhang; Yong Li
Journal:  Transl Cancer Res       Date:  2021-07       Impact factor: 1.241

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.